Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (DARE) reported peer-reviewed publication of a Phase 1 study in healthy men showing its proprietary topical Sildenafil Cream, 3.6% produces substantially lower systemic exposure than 50 mg oral sildenafil.
The open-label, randomized study enrolled 62 men who received single doses of 36 mg or 71 mg topical sildenafil cream, with or without condom use, or a 50 mg oral tablet. All 14 treatment-emergent adverse events were mild, with 7 occurring in 5 participants given oral sildenafil, and there were no serious events, severe events, deaths, or discontinuations. Mean maximum plasma concentrations for topical groups ranged from 969 to 1,274 pg/mL versus 238,000 pg/mL for oral dosing, with relative bioavailability of 2.55% to 3.20%. At the 71 mg topical dose, mean maximum plasma concentration was about 187-fold lower and overall exposure (AUClast and AUCinf) about 33–34-fold lower than the 50 mg oral dose.
Daré Bioscience (DARE) announced that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available on-demand starting September 11, 2026, at 7:00 a.m. ET.
The presentation, led by President and CEO Sabrina Martucci Johnson, covers an overview of the company and recent corporate and clinical developments. It can be accessed via the conference link or through the Presentations, Events & Webcasts page in the Investors section of darebioscience.com and will remain available for 90 days. Management will also attend the conference in New York, NY, from September 14–16, 2026, for one-on-one investor meetings.
Daré Bioscience (NASDAQ: DARE) announced a new NIH funding award of approximately $908,000 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to support year-long preclinical development of DARE-PTB2, an early-stage investigational program for preventing idiopathic preterm birth.
The notice of award also includes recommended future-year support of about $1.3 million for initial pharmacokinetic, safety, and toxicity studies. This non-dilutive grant builds on an earlier $400,000 NICHD award in July 2023 that funded proof-of-concept target validation studies with the University of South Florida.
Daré Bioscience (NASDAQ: DARE) announced that President and CEO Sabrina Martucci Johnson participated in the Virtual Investor “Why Now” on-demand series, where she presented the company’s investment thesis. The webcast highlights Daré’s mission to advance innovative, science-based and capital-efficient solutions addressing significant unmet needs in women’s health.
According to Daré Bioscience, Ms. Johnson emphasized the company’s first direct product launch, its diversified development pipeline, and its collaboration-driven strategy. The video webcast is available for on-demand viewing, and additional information about Daré’s focus areas across contraception, menopause, sexual and vaginal health, fertility, and infectious disease is available on the company’s website.
Daré Bioscience (NASDAQ: DARE) announced publication in Menopause - The Journal of The Menopause Society of Phase 1 data for its proprietary topical sildenafil cream 3.6% in healthy postmenopausal women. The open-label, within-participant dose-escalation study enrolled 21 women (mean age 57); 19 completed all four treatment periods.
Participants received a placebo dose followed by escalating doses of Sildenafil Cream containing 50 mg, 100 mg and 200 mg sildenafil citrate, with 14- to 16-day washout periods. According to Daré, all evaluated doses were well tolerated, all treatment-emergent adverse events were mild, and no serious or cardiac treatment-emergent adverse events or symptomatic orthostatic hypotension were observed.
At the 100 mg dose, which was later used in Daré’s Phase 2b RESPOND study, maximum plasma sildenafil concentration was approximately 3,810 pg/mL, about two orders of magnitude below the 450,000 pg/mL reported in men after a 100 mg oral dose in a separate study. Daré stated that these findings support localized genital delivery with limited systemic exposure and reinforce the potential of its DARE to PLAY compounded sildenafil cream and its proprietary Sildenafil Cream, which it aims to advance under the FDA’s 505(b)(2) pathway.
The company is continuing activities to seek future FDA approval of its proprietary Sildenafil Cream while, in parallel, launching DARE to PLAY Sildenafil Cream, a 503B compounded version. According to Daré, prescription dispensing and initial product revenue for DARE to PLAY Sildenafil Cream are expected to begin in Q3 2026, creating an opportunity for earlier commercial exposure while the regulatory program proceeds.
Daré Bioscience (NASDAQ: DARE) announced that President and CEO Sabrina Martucci Johnson participated in a Virtual Investor CEO Connect segment, where she described the company’s transition from a development-stage biotech to a commercial-stage women’s health company.
According to Daré Bioscience, the discussion highlighted the launch of Flora Sync LF5™ and preparations for DARE to PLAY™ Sildenafil Cream to begin generating revenue. Johnson also described efforts to build a scalable commercial infrastructure to support multiple products, including customer acquisition, provider engagement and market access initiatives.
The segment further covered pipeline developments, including Ovaprene’s positive interim Phase 3 results and DARE-HPV’s advancement into Phase 2, as well as potential value-driving catalysts the company sees over the next 12–18 months. The CEO Connect recording is now available for investors to view.
Daré Bioscience (NASDAQ: DARE) announced that founder, President and CEO Sabrina Martucci Johnson was named to the Forbes 2026 “50 Over 50: Innovation” list, highlighting leaders making significant impact later in their careers. The recognition coincides with Daré’s effort to evolve from a predominantly clinical-stage biotech into a multi-product women’s health company with commercial revenue opportunities.
According to Daré Bioscience, its portfolio now spans contraception, sexual health, menopause, vaginal health, fertility and infectious disease, and includes the FDA-approved bacterial vaginosis treatment XACIATO, partnered with Organon; pivotal Phase 3-stage Ovaprene, an investigational hormone-free monthly intravaginal contraceptive; and additional development programs such as DARE-HPV, advancing with non-dilutive government funding. Daré recently began direct-to-consumer commercialization of Flora Sync LF5 in July 2026 and is pursuing a dual-path strategy for DARE to PLAY Sildenafil Cream, including compounded product availability while exploring a potential FDA regulatory pathway.
Daré Bioscience (Nasdaq: DARE) entered into a definitive securities purchase agreement with institutional investors for a registered direct offering of 4,379,581 shares of common stock, or pre-funded warrants in lieu thereof, at $1.37 per share ($1.3699 per pre-funded warrant), priced at-the-market under Nasdaq rules. Gross proceeds are expected to be $6.0 million before fees and expenses.
In a concurrent private placement, investors will receive Series A warrants and Series B warrants to purchase up to 4,379,581 shares each, at an exercise price of $1.37 per share. Both warrant series become exercisable only after required stockholder approval; Series A warrants have a five-year term from initial exercise, and Series B warrants have a two-year term. Closing of the registered direct offering and concurrent private placement is expected on or about August 17, 2026, subject to customary conditions, with Ladenburg Thalmann & Co. acting as exclusive placement agent.
Daré Bioscience (NASDAQ: DARE) reported second quarter 2026 revenue of $0.19 million, up from negative revenue in 2025, driven by research and development services for Gates Foundation agreements. Cost of revenues was $0.32 million. Selling, general and administrative expenses were $2.59 million and R&D expenses were $0.24 million, reflecting increased contra-R&D funding.
Net loss narrowed to $3.0 million, or $0.20 per share, versus $4.0 million, or $0.45 per share, a year earlier. As of June 30, 2026, cash and cash equivalents were $12.6 million, with a working capital deficit of $0.24 million and stockholders’ deficit of $0.56 million. The company highlighted the launch of Flora Sync LF5, upcoming DARE to PLAY Sildenafil Cream revenue, positive interim Phase 3 Ovaprene results, and initiation of the Phase 2 DARE-HPV study supported by ARPA-H and NIH funding.
Daré Bioscience (NASDAQ: DARE) will host a corporate update conference call and webcast at 4:30 PM Eastern Time on Thursday, August 13, 2026, to review second-quarter 2026 financial results and provide a company update. Investors can join by phone using conference ID 3808585 or via the Investors section of the company’s website, where the live webcast and a 90-day replay will be available.